Thereby, it is needed to carry on the experiment in docetaxel-resistant prostate cancer in vitro and in vivo to establish USP8 as a therapeutic target for not only prostate cancer but also docetaxel-resistant prostate cancer. This evidence concerns the gene USP8 and prostate carcinoma.